MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Search

Lantheus Holdings Inc

Open

BrancheGesundheitswesen

104.26 2.3

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

100.47

Max

104.17

Schlüsselkennzahlen

By Trading Economics

Einkommen

-143M

-12M

Verkäufe

12M

391M

KGV

Branchendurchschnitt

23.078

57.333

EPS

1.59

Gewinnspanne

-3.014

Angestellte

808

EBITDA

-177M

22M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+24.92% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.5B

7B

Vorheriger Eröffnungskurs

101.96

Vorheriger Schlusskurs

104.26

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Lantheus Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Apr. 2025, 23:27 UTC

Top News

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28. Apr. 2025, 23:07 UTC

Top News

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28. Apr. 2025, 23:03 UTC

Ergebnisse

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28. Apr. 2025, 23:47 UTC

Market Talk

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28. Apr. 2025, 23:17 UTC

Ergebnisse

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28. Apr. 2025, 23:17 UTC

Ergebnisse

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28. Apr. 2025, 23:08 UTC

Ergebnisse

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28. Apr. 2025, 23:08 UTC

Ergebnisse

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28. Apr. 2025, 23:08 UTC

Ergebnisse

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28. Apr. 2025, 22:57 UTC

Top News

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28. Apr. 2025, 22:55 UTC

Ergebnisse

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28. Apr. 2025, 22:55 UTC

Ergebnisse

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28. Apr. 2025, 22:55 UTC

Ergebnisse

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28. Apr. 2025, 22:46 UTC

Ergebnisse

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Peer-Vergleich

Kursveränderung

Lantheus Holdings Inc Prognose

Kursziel

By TipRanks

24.92% Vorteil

12-Monats-Prognose

Durchschnitt 127.13 USD  24.92%

Hoch 140 USD

Tief 110 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lantheus Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

8

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

100.48 / 104Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.